Can Two Toolkits Make a Sustainable Business?
Executive Summary
Things went downhill for population genetics company Gemini Genomics PLC after its IPO in July 2000, the most successful public offering of a UK company that year. Less than twelve months after raising $97 million on Nasdaq (where it hoped for greater visibility than from a London listing, given the paucity of UK genomics companies), the company has been bought by the German-American Sequenom Inc., in an all-paper deal worth about $224 million . Taking into account Gemini's net assets of $81.4 million, this values its technology at less than $150 million, a far cry from the company's $450 million market capitalization at its IPO.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.